<DOC>
	<DOCNO>NCT00835185</DOCNO>
	<brief_summary>The purpose study determine IMC-11F8 combination chemotherapy effective treating colorectal cancer ( CRC ) .</brief_summary>
	<brief_title>Study IMC-11F8 Participants With Colorectal Cancer</brief_title>
	<detailed_description>The purpose study evaluate anti-tumor activity ( best overall response ) anti-epidermal growth factor receptor ( EGFR ) monoclonal antibody IMC-11F8 administer combination mFOLFOX-6 chemotherapy regimen treatment-naive , locally-advanced metastatic CRC participant .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Histologicallyconfirmed , EGFRdetectable EGFRundetectable CRC Locallyadvanced unresectable metastatic adenocarcinoma colon rectum At least 1 unidimensionalmeasurable target lesion compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) ; target lesion ( ) must lie within irradiated area Age ≥18 year Life expectancy ≥6 month Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 study entry Adequate hematologic function , evidence absolute neutrophil count ( ANC ) ≥1.5 x 10^9 liter ( L ) , hemoglobin ≥10 gram per deciliter ( g/dL ) , platelets ≥100 x 10^9/L Adequate hepatic function define total bilirubin ≤1.5 milligrams per deciliter ( mg/dL ) , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤2.5 x upper limit normal ( ULN ) ( 5.0 x ULN case liver metastasis ) , alkaline phosphatase ( AP ) ≤2.5 x ULN ( 5.0 x ULN case liver metastasis ) Adequate renal function define serum creatinine ≤1.5 x ULN , creatinine clearance ≥ 60 milliliter per minute ( mL/min ) , serum albumin ≥lower limit normal ( LLN ) Participant 's relevant toxicities/effects prior therapy [ surgery/radiation therapy ( RT ) ] must recover stable chronic level Participant agree use adequate contraception study period 4 week last dose study treatment . Participants must notify principal investigator partner become pregnant . Participant provide sign Informed Consent Has receive prior systemic chemotherapy locallyadvanced unresectable metastatic CRC . Has receive prior radiotherapy &gt; 25 % bone marrow Has document and/or symptomatic brain metastasis Has participate clinical study nonapproved experimental agent procedure within 12 week study entry Has receive previous therapy monoclonal antibody Has receive previous therapy agent target EGFR Has serious concomitant medical condition include active uncontrolled infection cardiac disease , opinion investigator , could compromise participant study . On chronic nontopical corticosteroid treatment &gt; 6 month dose &gt; 10 milligram per day ( mg/day ) prednisolone equivalent study entry , opinion investigator could compromise participant study Has know dihydropyrimidine dehydrogenase deficiency Has know allergy treatment component Has acute subacute intestinal occlusion Has peripheral neuropathy ≥Grade 2 Has history malignancy , exception curatively treat nonmelanoma skin cancer carcinoma situ cervix If female , pregnant ( confirmed urine serum beta human chorionic gonadotropin test ) breastfeeding Has receive prior autologous allogeneic organ tissue transplantation Has interstitial pneumonia interstitial fibrosis lung Has pleural effusion ascites cause ≥Grade 2 dyspnea Has psychological , familial , sociological , geographical condition permit adequate study followup , compliance protocol , signature Informed Consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Colorectal Neoplasms</keyword>
</DOC>